NCT03678883 2024-11-079-ING-41 in Patients with Advanced CancersActuate Therapeutics Inc.Phase 2 Active not recruiting350 enrolled
NCT02034110 2023-08-21Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare CancersNovartisPhase 2 Completed206 enrolled 40 charts 2 FDA